The biopharmaceutical company paused the global clinical trial after a participant in the United Kingdom suffered an adverse reaction.
The New York Times reported the illness as transverse myelitis, an inflammation of the spinal cord that interrupts messages that nerves send throughout the body.
AstraZeneca has initiated a safety review and has not given a timeline for when the trial may resume.
More articles on spine:
The evolution of MIS SI joint: 6 key developments since CMS upped rates 27%
Losing its orthopedic provider to a competitor, New York system taps new partner
Orthopedic rankings, robotics & more: 6 key developments at Mayo Clinic during the pandemic
